1. Home
  2. ELLO vs FATE Comparison

ELLO vs FATE Comparison

Compare ELLO & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ELLO

Ellomay Capital Ltd (Israel)

SELL

Current Price

$17.91

Market Cap

255.4M

Sector

Utilities

ML Signal

SELL

Logo Fate Therapeutics Inc.

FATE

Fate Therapeutics Inc.

N/A

Current Price

$1.02

Market Cap

260.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ELLO
FATE
Founded
1987
2007
Country
Israel
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
255.4M
260.0M
IPO Year
1998
2013

Fundamental Metrics

Financial Performance
Metric
ELLO
FATE
Price
$17.91
$1.02
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
★ $5.72
AVG Volume (30 Days)
2.1K
★ 1.5M
Earning Date
12-01-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 29.88
EPS
★ N/A
N/A
Revenue
N/A
★ $6,646,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18.72
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$17.00
$0.95
52 Week High
$30.34
$3.23

Technical Indicators

Market Signals
Indicator
ELLO
FATE
Relative Strength Index (RSI) 41.27 19.93
Support Level $17.54 N/A
Resistance Level $20.40 $1.38
Average True Range (ATR) 0.60 0.16
MACD -0.27 -0.09
Stochastic Oscillator 14.92 1.75

Price Performance

Historical Comparison
ELLO
FATE

About ELLO Ellomay Capital Ltd (Israel)

Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions. Geographically, the company operates in segments: Italy; Spain; USA; Netherland and Israel. It derives maximum revenue from Spain.

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Share on Social Networks: